Vaccitech, which developed the technology underlying Oxford’s covid vaccine, has priced its shares and will raise more than $110m in its IPO.

Vaccitech, a UK-based vaccine developer spun out of University of Oxford, priced its shares at $17 yesterday and will raise more than $110m when it begins trading on the Nasdaq Global Market today. The spinout will issue 6.5 million American Depositary Shares (ADSs), representing the same number of ordinary shares. It will trade using the…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.